Citations

Clear

6729 citation(s) found for "Li, Mark".

Multi‐Frequency Electrocochleography Results in Fewer Drop Alarms During Cochlear Implant Insertion
Espahbodi, Mana , Syed, Ali, Tu, Alex, Seidman, Michael D. , Danner, Christopher J., Allen, Kyle P., Bartels, Loren J., Ahsan, Syed F. , Voelker, Courtney C. J. , Deep, Nicholas L. , Chiffer, Rebecca C., Elrakhawy, Mohamed, Miller, Matthew W., Lin, Harrison W., Djalilian, Hamid R. , Angeli, Simon I., Kim, H J, Widick, Mark H., Stidham, Katrina R. , Patel, Neil S. , Koka, Kanthaiah , Hunter, Jacob B , Djalilian, Hamid R , Stidham, Katrina R , Gurgel, Richard Klaus , Doerfer, Karl W , Harris, Michael S , Danner, Christopher, Bartels, Loren Jay, Hunter, Jacob B. , Michaelides, Elias M. , Miller, Matthew W, Vivas, Esther , Angeli, Simón I., Hoa, Michael , Harris, Michael S.

Mayo Clinic

The Laryngoscope | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70592 | PMID 42084107 Get It

ABSTRACT Objective To evaluate intracochlear electrocochleography (ECochG) amplitude parameters during cochlear implantation (CI) using a novel multi‐frequency ECochG algorithm. Methods A multi‐institutional, prospective cohort study was performed at 18 high‐volume CI centers. The inclusion criteria were adults with sensorineural hearing loss and audiometric thresholds of ≤ 90 dB hearing level at 500 Hz undergoing CI with Advanced Bionics (Valencia, CA) Ultra 3D devices between 2024 and 2025. ECochG recordings were performed with simultaneous multi‐frequency stimulation of four frequencies between 125 and 4000 Hz during cochlear implant insertion. Concurrent multi‐frequency recording allowed extraction of amplitude and phase of each frequency individually. Post hoc analysis was performed to determine the difference in the number of drop alarms between single‐ and multi‐frequency ECochG. An ECochG amplitude drop of 6 dB was defined as a drop alarm. Insertion track patterns were compared between single‐ and multi‐frequency ECochG. Results One hundred ninety‐five ears were included. Mean number of drop alarms for the single‐frequency algorithm was 1.72 (95% CI: 1.52, 1.92; median 1) compared to 0.42 (95% CI: 0.31, 0.53; median 0) for multi‐frequency; p < 0.001. The number of Type C patterns (rise in amplitude during insertion followed by a drop) decreased with the multi‐frequency ECochG algorithm compared to the single‐frequency ECochG algorithm. The number of Type D patterns (no‐response) decreased, indicating that multi‐frequency ECochG generated more responses across the cochlea than single‐frequency ECochG. Conclusions A novel multi‐frequency ECochG algorithm during CI is associated with fewer drop alarms and altered insertion track patterns, which may provide a more accurate assessment of the cochlear microenvironment. Level of Evidence 3.
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Mendieta, Guiomar , Ridker, Paul M. , Borlaug, Barry A. , Ducharme, Anique , Lam, C S P, Voors, Adriaan A, Auerbach, Pernille, Cikes, Maja, Fudim, Marat, Hvelplund, Anders, Lam, Carolyn S.P. , Lam, Carolyn S P , Petrie, Mark C , Ridker, Paul M. , Borlaug, Barry A , Ducharme, Anique , Voors, Adriaan A. , Auerbach, Pernille, Čikeš, Maja , Fudim, Marat , Michelsen, Marie Mide , Petrie, Mark C.

Mayo Clinic

European Journal of Heart Failure | May 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag153 | PMID 42106986 Get It

Abstract Aims We hypothesized that targeting interleukin-6—a cytokine central to NOD-like receptor protein 3 (NLRP3) inflammasome activation that is associated with both the onset and progression of heart failure (HF)—may be beneficial in patients with HF and circulating evidence of cardiovascular inflammation but without overtly reduced ejection fraction (EF). We describe the rationale and design of two clinical trials (ATHENA and HERMES) investigating ziltivekimab, a human monoclonal antibody directed against the interleukin-6 ligand, in patients with HF and mildly reduced or preserved EF (HFmrEF/HFpEF) and cardiovascular inflammation. Methods ATHENA (n = 673) and HERMES (n = 4900) are international, multi-centre, double-blind, placebo-controlled trials randomizing adults with HFpEF/HFmrEF and cardiovascular inflammation (high-sensitivity C-reactive protein ≥2 mg/l) to ziltivekimab 15 mg or placebo, administered subcutaneously once monthly on top of standard of care. Eligible participants have a left ventricular EF &gt;40%, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), and serum high-sensitivity C-reactive protein ≥2 mg/l. The primary endpoint in ATHENA is the change in Kansas City Cardiomyopathy Questionnaire—Clinical Summary Score at 12 months. The primary endpoint in HERMES is time to first composite of cardiovascular death, hospitalization for HF, or urgent HF visit. ATHENA has a fixed duration of 12 months, whereas the HERMES trial is event driven (∼845 adjudicated primary events) with a minimum exposure of 6 months from randomization to the last treatment visit. Conclusion ATHENA and HERMES will investigate the effect of ziltivekimab in HFpEF/HFmrEF and cardiovascular inflammation. ATHENA will determine the effect of ziltivekimab on health status. HERMES will determine the efficacy and safety of ziltivekimab on morbidity and mortality.
Abstract TU205: The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results from a Randomized Controlled Trial
Demmer, Ryan, Pope, Zachary, Avenido, Francis Ryan, Mitchell, Nathan, Hubbard, Paige Richmond, Johnson, Stephen, McDonough, DJ, Rydell, Sarah, Johnson, Abigail, Pereira, Mark, Demmer, Ryan T. , Pope, Zachary , Mitchell, Nathan R , Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta , Rydell, Sarah A.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu205 Get It

Objective: To test the effect of physical activity on the gut microbiome and circulating short chain fatty acids among sedentary overweight/obese adults with prediabetes. We hypothesized that randomization to increased physical activity would result in gut microbiome changes. Methods: \We randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) Intervention Group: Invited to engage in home-based moderate intensity walking 3x/week for 30 minutes/session in weeks 1-4 and for 45 minutes/session during weeks 5-8 of the 8-week intervention; or 2) Control Group: Maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with short-chain fatty acids (SCFA) measured from serum collected at baseline and week 8. Taxonomic and functional profiling were performed on the metagenomic reads; alpha diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for alpha-diversity and SCFA levels. Results: We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase and 77 were randomized. Participants were 51.4±8.9 years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3±13.2 while mean BMI was 34.4±5.7. In comparison to the control group, the intervention group experienced decreased alpha diversity as characterized by Shannon, Richness, and Faith’s diversity indices by week 8 of the intervention (P<0.05). SCFA levels trended towards improvement in the intervention group, but the results were not statistically significant. Functional analysis of KEGG ontologies revealed themes consistent with a microbiome with enhanced metabolic activity and host-relevant metabolic signaling (Figure). Conclusions: Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight/obesity and prediabetes.
Abstract MPTH62: Midlife Resistance Exercise Behaviors and Incident Heart Failure with Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study
McDonough, DJ, Avenido, Francis Ryan, Demmer, Ryan, Gabriel, Kelley, VanWagner, Lisa, Borlaug, Barry, Stovitz, Steven, Meyer, Markus, Erickson, Darin, Palta, Priya, Pereira, Mark, Demmer, Ryan T. , Gabriel, Kelley Pettee , VanWagner, Lisa B , Stovitz, Steven D. , Meyer, Markus

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.mpth62 Get It

Introduction: Heart failure (HF) with preserved ejection fraction (HFpEF) is now the predominant HF subtype, largely driven by the syndemic of physical inactivity and overweight/obesity in an aging population. Deranged skeletal muscle energetics and regional ectopic adipose depots are key cardiometabolic pathways in the pathogenesis of HFpEF, both of which may be favorably modified by 1-2 hours/week of resistance exercise (RE). However, its association with HFpEF risk has not been thoroughly examined. We investigated the association between midlife RE behaviors and incident HFpEF in the Atherosclerosis Risk in Communities (ARIC) study. Hypothesis: Participation in RE at midlife is inversely associated with the risk of incident HFpEF. Methods: Our exposure (RE)—including weightlifting and bodyweight resistance exercises—was assessed using the validated Baecke questionnaire and reported weekly RE duration was averaged across Visits 1 and 3 (1987-1995). We dichotomized averaged RE as 0 hr/wk (‘No RE’, reference) and >0 hr/wk (‘Any RE’). Our outcome (incident HFpEF) was identified through committee-adjudicated HF hospitalizations (January 1, 2005 to December 31, 2023) using medical chart abstraction. Participants with prevalent HF, death, or loss to follow-up before January 1, 2005 were excluded. We constructed Cox regression models to evaluate the association between midlife RE and incident HFpEF. Model 1 adjusted for age, sex, race, field center, education, smoking status, alcohol consumption, and non-RE physical activity. Given that adiposity may lie on the causal pathway, waist-height ratio (WHtR; both measured in cm) was added in Model 2. Results: 10,751 Black and White participants (803 incident HFpEF cases) were analyzed over a median follow-up time of 14.4 years (mean±SD Visit 1 age, 53.3±5.6 years; average Visit 1 and 3 WHtR, 0.58±0.08; 24.7% Black; 57.4% female). 1,217 participants (11.3%) reported engaging in RE at Visits 1 and/or 3, with a median duration of 0.84 hr/wk (IQR, 0.50-1.61). Compared to No RE, the fully adjusted hazard ratio (HR) for Model 1 for Any RE was: 0.78 (95% CI, 0.61-1.00, P = 0.05). The association was attenuated after adjustment for WHtR: HR = 0.84 (0.65-1.07, P = 0.16). Conclusion: Participation in RE at midlife is associated with a 22% lower risk of incident HFpEF. To inform public health and clinical guidelines, further studies are needed to clarify the role of RE in HFpEF prevention.
Vitamin D deficiency and systemic inflammation in hidradenitis suppurativa: clinical correlates in a retrospective cohort
Shrestha, Raslina , Van, Duc L., Tran, Hue T T, Ma, Jun, Alavi, Afsaneh, Davis, Mark, Wetter, David A, Lu, Kurt Q. , Nguyen, Giang H, Nguyen, Giang Huong , Tran, Hue T, Nguyen, Giang H , Tran, Hue T.T. , Alavi, Afsáneh , Davis, Mark D.P. , Wetter, David A.

Mayo Clinic

British Journal of Dermatology | April 30, 2026 | Volume: 195 | Issue: 2 | Pages: 339-341

10.1093/bjd/ljag157 | PMID 42056003 Get It

Vitamin D deficiency is frequently reported in hidradenitis suppurativa (HS), but its clinical significance remains unclear. In a retrospective cohort of 503 patients, deficiency was common and associated with demographic and metabolic factors but not with treatment-defined severity. Vitamin D deficiency was independently associated with elevated C-reactive protein, suggesting a link with systemic inflammation.
Editorial Comment
Tyson, Mark

Mayo Clinic

Journal of Urology | April 29, 2026 | Volume: 216 | Issue: 2 | Pages: 205-205

10.1097/ju.0000000000005066 | PMID 42054560 Get It

Retrieval-Augmented Generation in Oncology: Promises, Pitfalls, and Early Applications
Thaker, Nikhil G. , Liu, Wei, Waddle, Mark, SHOWALTER, TIMOTHY, Luh, Join, Levitt, Chad, Ning, Matthew, Loaiza-Bonilla, Arturo, Hong, Julian, Mastroleo, Federico , Showalter, Timothy N. , Luh, Join Y. , Loaiza‐Bonilla, Arturo

Mayo Clinic

AI in Precision Oncology | April 29, 2026 | Volume: 3 | Issue: 2-3 | Pages: 34-45

10.1177/2993091x261446348 | PMID 42305950 Get It

Retrieval-augmented generation (RAG) is rapidly emerging as a transformative paradigm for large language models (LLMs), especially in high-stakes domains like oncology that demand precision, factual grounding, and up-to-date knowledge. By pairing LLMs with external knowledge repositories, RAG systems explicitly ground model outputs in relevant retrieved documents, helping to reduce hallucinations and ensure responses reflect current evidence. In oncology, where clinical knowledge evolves continually with new research and drug approvals, RAG offers a way to integrate the latest data (e.g., trial results, guidelines, genomic databases) into decision-making. This review synthesizes the technical foundations of RAG, including its architecture and key components, and examines current applications in oncology such as clinical decision support, patient education, radiology reporting, pathology analysis, and genomics-driven precision medicine. We highlight recent studies that demonstrate RAG’s potential—for instance, improving treatment recommendations by incorporating genetic profiles and literature, and enhancing diagnostic accuracy by integrating guidelines. We also discuss emerging developments like multimodal RAG (combining text with imaging or other data), ensemble model approaches, and new explainability tools that trace model outputs to sources. Finally, we critically analyze the limitations and challenges of deploying RAG in healthcare, including computational costs, retrieval errors, noise or conflicts in retrieved information, and ethical and regulatory considerations. While RAG-based systems show promise in augmenting oncologists’ expertise with timely knowledge, careful implementation, high-quality curation of knowledge bases, and human oversight will be crucial for safe and effective adoption in clinical practice.
Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes
Akturk, Halis K, Nally, Laura M, Lal, Rayhan A, Warren, Mark , Demeterco-Berggren, Carla, Forlenza, Gregory P. , Reed, John Chip, Shulman, Dorothy I, Kipnes, Mark S, Bode, Bruce W. , Dewan, Asheesh K., Liljenquist, David R., Kudva, Yogish C, Niu, Fang , Yovanovich, Caroline, Shin, John , Cordero, Toni L. , McVean, Jennifer J F, Bergenstal, Richard M, Forlenza, Gregory P , Aktürk, Halis Kaan , Nally, Laura Marie , Lal, Rayhan , Demeterco‐Berggren, Carla , Reed, John H. Chip, Shulman, Dorothy I. , Kipnes, Mark, Kudva, Yogish C. , MCVEAN, JENNIFER J.F. , Vigersky, Robert A. , Bergenstal, Richard M.

Mayo Clinic

Diabetes Technology & Therapeutics | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15209156261444994 | PMID 42050782 Get It

Background: Given the faster onset and shorter duration of action of ultra-rapid insulin lispro-aabc (URLi, Lyumjev™ insulin), compared with insulin lispro (a rapid-acting insulin [RAI]), the present study investigated the safety and glycemic outcomes of MiniMed™ 780G advanced hybrid closed-loop (AHCL) use with URLi in youths and adults with T1D. Methods: This 19-site, single-arm, clinical trial enrolled children and adolescents (aged 7–17 years) and adults (aged 18–80 years) with T1D who underwent a run-in period (∼2 weeks) using open loop or automated basal only with an RAI (aspart or lispro), followed by a 3-month study period using URLi with AHCL (AHCL + URLi). End-of-study glycemic metrics and A1c were compared to predefined thresholds and to data from baseline/run-in. Use of recommended optimal settings (ROS, 100 mg/dL glucose target with an active insulin time [AIT] of 2 h) was also assessed. Results: In an intention-to-treat population ( N = 101 pediatric and N = 110 adult participants), percentage of time in range (%TIR) during the last ∼6 weeks of the study period was significantly greater than the predefined thresholds for both the pediatric and adult participants. A1c was unchanged in the pediatric cohort but significantly reduced in the adult cohort (from 7.4 ± 0.9% to 6.9 ± 0.6% [ P < 0.001]). Compared with run-in, study period %TIR and percentage of time in tight target range (%TITR) were significantly increased (pediatric mean %TIRΔ [17.4%] and %TITRΔ [16.0%], respectively, and adult mean %TIRΔ [10.6%] and %TITRΔ [11.6%], respectively; P < 0.001 for all). Additionally, % time above range for both groups was significantly reduced. Use of ROS allowed more participants to achieve recommended glycemic targets. There were no severe hypoglycemia or diabetic ketoacidosis events. Most caregivers agreed that mealtime versus premeal URLi delivery simplified pediatric meal management. Conclusions: Similar to previous studies investigating automated URLi delivery, URLi use in the MiniMed™ 780G system was safe, and glycemic outcomes were favorable for pediatric and adult participants.
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
Mukherjee, Sovanlal , Antony, Ajith , Trivedi, Kamaxi H. , Karbhari, Aashna , Bhinder, Khurram Khaliq , Truty, Mark, Johnson, Matthew P. , Goenka, Ajit H. , Patnam, Nandakumar G. , Chari, Suresh T , Goenka, Ajit Harishkumar , Zarrintan, Armin , Fletcher, Joel G. , Truty, Mark J. , Chari, Suresh T.

Mayo Clinic

Gut | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: gutjnl-2025-337266

10.1136/gutjnl-2025-337266 | PMID 42049489 Get It

Background Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary barrier to improving its otherwise poor rate of survival. Objective To develop and validate the Radiomics-based Early Detection MODel (REDMOD), an AI framework to identify subvisual radiomic signatures of pre-diagnostic PDA on standard-of-care CT. Designs REDMOD was trained on a multi-institutional cohort (n=969; 156 pre-diagnostic, 813 control) and tested on an independent set (n=493; 63 pre-diagnostic, 430 control), simulating a low prevalence (~1:6) early detection paradigm. The fully automated framework couples AI-driven segmentation with a heterogeneous ensemble architecture trained on a 40-feature radiomic signature derived from Synthetic Minority Over-sampling Technique (SMOTE)-balanced data. A tunable Youden Index-optimised classification threshold enables performance calibration without retraining. Validation included direct comparison with radiologists, longitudinal test–retest analysis and external specificity validation across two independent cohorts (n=539 and n=80). Results On an independent test set (n=493), REDMOD identified occult PDA (AUC 0.82; 73.0% sensitivity) at a median 475-day lead time. This represented nearly twofold higher sensitivity than radiologists (38.9%; p<0.001), which grew to nearly threefold (68.0% vs 23.0%) at >24 months lead time. REDMOD showed strong longitudinal stability (90–92% concordance) and generalisable specificity across multi-institutional (81.3%; n=539) and public (87.5%; n=80) datasets. Mechanistic analyses confirmed predictive power derived principally from multi-scale wavelet-filtered textural features (90% of selected signature), which outperformed unfiltered features (AUC 0.82 vs 0.74; p=0.007) in capturing subvisual architectural disruptions. Conclusions REDMOD is an automated, mechanistically grounded, longitudinally stable, externally validated AI that surpasses radiologists for PDA detection at its visually occult pre-diagnostic stage. These attributes position it for prospective validation in high-risk cohorts, a necessary step towards shifting the paradigm from late-stage symptomatic diagnosis to proactive pre-clinical interception.
The Evolving Identity of Transurethral Resection of Bladder Tumor: Redefining Quality in an Era of Alternatives
Nguyen, Mimi, Tyson, Mark, Nguyen, Mimi

Mayo Clinic

Journal of Urology | April 28, 2026 | Volume: 216 | Issue: 2 | Pages: 179-181

10.1097/ju.0000000000005093 | PMID 42048784 Get It